ClinicalTrials.gg
RecruitingNCT04626687Updated Jan 5, 2024

ACOART Paclitaxel SVD:Paclitaxel Coated Coronary Balloon Catheter in Treatment of Coronary Small Vessel Diseases

An interventional study of test DCB and RESTORE DCB in Coronary Disease, sponsored by Acotec Scientific Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Acotec Scientific Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Apr 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 224 studies in Coronary Disease with a site in China — 68 open to participants now, 78 under way, 3 of them phase 3. Coronary Disease · China.

Planned enrollment
66th of 142
230 · median 220
Started
2021
with 19 others
No phase
87 of 224
27 open now
Primary completion
2024-12
later than 11 of 77 live
Registered
118th of 224
by date

Among the 224 studies in Coronary Disease with a site in China, this one is the 66th largest by planned enrollment of the 142 interventional ones that give a count, is one of 20 that started in 2021, is one of 87 with no phase, reaches primary completion later than 11 of the 77 other live ones, and was the 118th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

68 of the 224 studies in Coronary Disease with a site in China are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 224 studies in Coronary Disease with a site in China, or all of them as a file.
02

Study summary

The purpose of the trial is to determine whether DCB made by Acotec Scientific is not inferior to RESTORE DEB made by CARDIONOVUM GmbH in treatment of small vessel coronary disease.

Read the detailed description

This is a prospective, multi-center, randomized-controlled clinical trial to verify the efficacy and safety of DCB made by Acotec Scientific versus RESTORE DEB in treatment of small vessel coronary disease. And the primary endpoint is angiographic restenosis at 9 months post-procedure.

03

Conditions studied

  • Coronary Disease

Browse trials for

Keywords

  • coronary small vessel diseases
  • DCB
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 80 years of age
  • Subjects with symptomatic coronary artery disease with stable and unstable angina pectoris or secondary evaluation of stenosis after acute myocardial infarction (MI) and asymptomatic subjects with coronary atherosclerotic stenosis causing myocardial ischemia determined by the investigator
  • Subjects with single, de novo lesion with stenosis of more than 70% (or more than 50% combined with symptoms of ischemia) in a vessel with visually estimated reference vessel diameter (RVD) ≥ 2.00 mm and ≤ 2.75 mm, and ≤ 26 mm in length.
  • Subject must agree to clinical follow-up at 1, 6, 9, 12 months, and angiographic follow-up at 9 months.
  • Subject can understand the study objectives psychologically and linguistically and shows sufficient compliance to the study protocol. Subjects express acceptance of the risks and benefits described in the form.

Exclusion criteria

Exclusion Criteria:

  • AMI within 1 week.
  • Subject has congestive heart failure or IV.
  • Subject with \< 35%.
  • Subject has undergone heart transplantation.
  • Subject has cardiac arrhythmias, such as high-risk ventricular premature beat and/or ventricular tachycardia.
  • Subject suffered stroke, gastrointestinal bleeding or active ulcer within the past 6 months, or with conditions associated with high risk of bleeding.
  • Subject with a history of leukopenia (white blood cell count of \< 3×109/L for >3 days), neutropenia (ANC\<1000/mm3 for >3 days) or thrombocytopenia ( \<100,000/mm3).
  • Known renal insufficiency (\<30 ml/min).
  • Subject who is forbidden to use anticoagulation agents or anti-platelet drugs, and tolerate Aspirin or Clopidogrel.
  • less than 12 months, or subjects who cannot complete 12-month follow-up.
  • Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure.
  • Subject is currently participating in another drug or device study that has not yet completed its primary endpoint.
  • Subject unsuitable for study according to the investigator due to the investigator due to other reasons related to diseases.
  • Angiography exclusions:Target lesion: Total occlusion lesion (TIMI 0), heavy calcified lesion that cannot be successfully dilated, bifurcation lesion (side branch ≥ 2.0 mm in diameter), restenosis lesion, thrombotic lesion, or left main disease;Non-target lesion: More than 2 non-target lesions or non-target lesion cannot be successfully treated.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    test DCB group

    use the DCB made by Acotec Scientific

    Device: test DCB

  • Active comparator
    RESTORE DCB group

    use the DCB made by CARDIONOVUM GmbH

    Device: RESTORE DCB

Interventions

  • Devicetest DCB

    use paclitaxel coated coronary balloon catheters to treat SVD

  • DeviceRESTORE DCB

    use paclitaxel coated coronary balloon catheters(RESTORE DCB) with NMPA approval indication for treating SVD

06

What researchers measure

Primary outcomes

  1. Angiographic percent diameter stenosis

    (1-Segmental minimum lumen diameter \[MLD\]/ segmental reference vessel diameter \[RVD\]) ×100%

    Time frame: at 9 months post-procedure

Secondary outcomes

  1. Acute success

    Including instrument success rate, lesion success rate and surgical success rate

    Time frame: in the procedure

  2. Rate of target lesion failure

    A composite of cardiac death, target-vessel related myocardial infarction, and ischemia-driven target lesion revascularization

    Time frame: within 12 months post-procedure

  3. Diameter stenosis in-device

    (1-the minimum cavity diameter of the device \[MLD\] / the reference vessel diameter of the device \[RVD\]) ×100%

    Time frame: at 9 months post-procedure

  4. Late lumen loss

    Loss of late lumen in the segment and device

    Time frame: at 9 months post-procedure

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Dec 2024, 44 months after the start.

Of 202 interventional studies with no phase under Coronary Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 51. This study's planned 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2020
First posted
Nov 12, 2020
StartActual
Apr 6, 2021
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04626687
Lead sponsor
Acotec Scientific Co., Ltd
Collaborators
Shanghai Tongji Hospital, Tongji University School of Medicine
Responsible party
Sponsor
First posted
Nov 12, 2020
Start date
Apr 6, 2021
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Jan 5, 2024

Study contacts

Xuebo Liu, MD
Contact
lxb70@hotmail.com
021-56051080
Xuebo Liu, MD
principal investigator · Shanghai Tongji Hospital, Tongji University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion